Verve Therapeutics(US:VERV) Prnewswireยท2024-09-09 14:33Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Verve Therapeutics, Inc. regarding a class action lawsuit alleging misleading statements and omissions related to the company's clinical trial and product claims [1][2]. Group 1: Allegations - The complaint alleges that during the class period from August 9, 2022, to April 1, 2024, Verve Therapeutics did not fully disclose the circumstances under which the Heart-1 Phase 1b clinical trial of its investigational gene editing medicine, VERVE-101, would be halted [1]. - It is claimed that the defendants overstated the potential benefits of their proprietary lipid nanoparticle delivery system [1]. - As a result of these actions, the statements made by the defendants regarding the company's business, operations, and prospects were materially false and misleading [1]. Group 2: Class Action Details - Shareholders who purchased shares of VERV during the specified class period are encouraged to register for the class action, with a deadline set for October 28, 2024 [2]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the lifecycle of the case [2]. - There is no cost or obligation for shareholders to participate in this case [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered due to deceit, fraud, and illegal business practices [3]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors who incurred losses from misleading statements or omissions that led to artificial inflation of stock prices [3].